Paeonolum protects against MPP\(^+\)-induced neurotoxicity in zebrafish and PC12 cells

Xi-Lin Lu\(^1,2,3\), Yue-Hao Lin\(^4\), Qi Wu\(^1,2,3\), Feng-Juan Su\(^1,2,3\), Cheng-Hui Ye\(^5\), Lei Shi\(^6\), Bai-Xuan He\(^1,2,3\), Fei-Wen Huang\(^1,2,3\), Zhong Pei\(^1,2,3\)* and Xiao-Li Yao\(^1,2,3\)*

Abstract

Background: Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting 2% of the population aged over 65 years old. Mitochondrial defects and oxidative stress actively participate in degeneration of dopaminergic (DA) neurons in PD. Paeonolum, a main component isolated from Moutan cortex, has potent antioxidant ability. Here, we have examined the effects of paeonolum against MPP\(^+\)-induced neurotoxicity in zebrafish and PC12 cells.

Methods: The overall viability and neurodegeneration of DA neurons was assessed in ETvmat2:green fluorescent protein (GFP) transgenic zebrafish, in which most monoaminergic neurons are labeled by GFP. Damage to PC12 cells was measured using a cell viability assay and assessment of nuclear morphology. Intracellular reactive oxygen species (ROS) and the level of total GSH were assessed. The mitochondrial cell death pathway including mitochondrial membrane potential, cytochrome C release and caspase-3 activity were also examined in PC12 cells.

Results: Paeonolum protected against MPP\(^+\)-induced DA neurodegeneration and locomotor dysfunction in zebrafish in a concentration-dependent manner. Similar neuroprotection was replicated in the PC12 cellular model of MPP\(^+\) toxicity. Paeonolum attenuated MPP\(^+\)-induced intracellular ROS accumulation and restored the level of total GSH in PC12 cells. Furthermore, paeonolum significantly inhibited the mitochondrial cell death pathway induced by MPP\(^+\).

Conclusions: Collectively, the present study demonstrates that paeonolum protects zebrafish and PC12 cells against MPP\(^+\)-induced neurotoxicity.

Keywords: Paeonolum, MPP\(^+\), Mitochondrial, Zebrafish, Total GSH, ROS

Background

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, affecting 2% of the population aged over 65 years. Clinically, PD patients mainly present with impairments in movement including: rigidity, resting tremor and postural instability [1,2]. Current treatments only reduce symptoms, but do not stop the progression of PD. Therefore, there is an urgent need to find more appropriate treatments that can prevent the PD progression.

Although the pathogenesis of PD remains largely unknown, both oxidative stress and mitochondrial dysfunction play pivotal roles in the pathogenesis of PD. For example, a defect in respiratory chain complex I activity in mitochondria has been observed in dopaminergic (DA) neurons in PD patients [3-7]. It is generally believed that both genetic susceptibility and environmental factors contribute to the etiology of PD. However, the majority of PD cases are sporadic, indicating a critical role for environmental factors in the pathogenesis of PD. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is an environmental toxin and can selectively damage DA neurons in the substantia nigra (SN) which in turn leads
to clinical symptoms similar to those of PD in humans [8,9]. Thus, MPTP and its metabolite MPP+ have been widely used to model PD in mammals [1,2,9,10].

Recently, model organisms such as zebrafish, are becoming powerful tools to study human diseases. Many of the basic physiological processes, metabolic signaling pathways and neurotransmitters in humans are conserved in such models [11,12]. Because model organisms are easy to grow and cost-effective to maintain, their use as a high-throughput strategy to identify new drug targets for human diseases is increasing. Recently, a zebrafish model of MPP+ toxicity has been established that can recapitulate many key features of PD including the specific degeneration of DA neurons and impairment of movement [13]. This model has been increasingly used as an in vivo tool for screening neuroprotective agents for PD.

MPP+-mediated neurotoxicity is believed to be mediated by inhibition of complex I activity and excessive formation of reactive oxygen species (ROS) [1,2,14]. Many antioxidants and agents that can protect the mitochondria have been reported to reduce MPTP-induced neurotoxicity and some have shown promising results in clinical trials with PD patients [2,15].

In recent years, natural antioxidants have become attractive targets for drug development in neurodegenerative diseases because of their demonstrated neuroprotective effects in animal models and low levels of toxicity. Paeonolum is a main component isolated from Moutan cortex. Paeonolum has been used as an anti-inflammatory drug for thousands of years in China. In addition to anti-inflammatory actions, paeonolum has many other pharmacological properties including anti-proliferative and antioxidative actions. Most importantly, paeonolum can easily cross the blood–brain barrier (BBB) which makes it an attractive compound for central nervous system (CNS) drug development [16]. The present study was conducted to investigate the neuroprotective potential of paeonolum against MPP+-induced neurotoxicity in zebrafish and PC12 cells.

### Methods

#### The isolation of paeonolum

The root bark of *Paeonia suffruticosa* belongs to Ranunculaceae. Paeonolum was isolated and purified by the State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, China, according to a published method [17]. The purity of the compound was >98%. Paeonolum was dissolved in dimethyl sulfoxide (DMSO) and stored at −20°C until use. The solution form of paeonolum was then diluted by PBS to the concentration needed. All reagents were purchased from Sigma (Sigma, Shanghai, China) unless otherwise stated.

#### Zebrafish MPP+ model and paeonolum treatment

The ETvmat2:GFP transgenic fish line was identified from a large-scale enhancer trap screen using a Tol2 vector containing a 249-bp zebrafish gata2 minimal promoter linked to a GFP reporter gene [18,19]. The fish line was maintained in a recirculating aquaculture system at 28.5°C. The MPP+ (Sigma-Aldrich) was dissolved in distilled water to 40 mM and was used at a final concentration of 100–1000 μM for the treatment. Embryos were obtained from the ETvmat2-GFP transgenic fish. At 22–24 hours post-fertilization (hpf), GFP-positive embryos were collected and dechorionated. Ten embryos were then transferred into a six-well plate containing 4 ml Holtfeter’s buffer with 0.003% phenylthiourea (Sigma-Aldrich) and MPP+. The MPP+-containing buffer was changed once after 2 days and at 5 days post-fertilization (dpf), the larval zebrafish were examined under a fluorescence microscope.

#### Testing of the locomotor activity

An automated computer tracking system was used to determine the locomotor activity of zebrafish larvae (Viewpoint Life Sciences Inc.). At 4 dpf, larval zebrafish were transferred to 96-well microplates and acclimated at 28°C overnight for 24 h. The 96-well microplates were then put into the zebrafish tracking box (Viewpoint Life Sciences Inc.) and activity of the zebrafish monitored using an automated video-tracking system (Viewpoint video-tracking system and software). The speed corresponding to the total length traveled by the larvae was divided by time and then analyzed (Viewpoint software). The results represent the mean swim speed of 10 larvae and are expressed in mm/s.

#### Morphology assay

Briefly, zebrafish (5 dpf) with or without compounds were anesthetized by treatment with 0.4% tricaine and mounted onto glass slide. Overall morphology of the zebrafish was visualized at 4× magnification under an OLYMPUS IX71 inverted microscope.

#### Cell culture and cell viability assay

PC12 (rat pheochromocytoma) cells were cultured in RPMI-1640 (Invitrogen, USA) supplemented with 10% heat-inactivated horse serum (Invitrogen, USA) and 5% heat-inactivated fetal calf serum (Invitrogen, USA) in an humidified incubator (Thermo electron corporation, USA) with 5% CO2 at 37°C. PC12 Cells were differentiated on collagen-coated plates by treating with 100 ng/ml nerve growth factor for 9 days and then washed with RPMI-1640 medium containing 1% fetal bovine serum, 24 h before experiments. Cellular viability was assessed using the MTT kit (MTT Cell Growth Kit, Chemicon, USA) according to the manufacturers instructions. Briefly,
PC12 cells were diluted to $1 \times 10^5$ cells/mL and plated at 100 µL per well in a 96-well microplate, then treated with various concentrations of paeonol and/or MPP$^+$ (250 µM) for 24 h. 10 µL of the MTT labeling reagent (0.5 mg/mL) was added into each well at 24 h after MPP$^+$ treatment and cells were further incubated with MTT in an humidified incubator at 37°C with 5% CO$_2$ and 95% air (v/v) at 90% humidity for 4 h to allow formation of purple formazan crystal. Four hours later, 100 µL of solubilization reagent was added to each well. Finally, the absorbance of the solubilized purple formazan crystals was measured using a microplate spectrophotometer at an absorbance wavelength of 570 nm. In order to examine MPP$^+$-induced nuclear morphology, PC12 cells were stained with the fluorescent dye, DAPI (2.5 µg/mL, Sigma, USA). PC12 cells (1 $\times$ 10$^5$ cells/mL) were treated with MPP$^+$ alone or in the presence of paeonol for 24 h at 37°C and changes in nuclear morphology of the cells were assessed by microscopic observation. Briefly, PC12 cells were fixed in 4% polylysine on ice for 15 min and then washed twice with PBS. The cells were then incubated with DAPI in PBS for 20 min at room temperature. Nuclear morphology of cells stained with DAPI was visualized under a fluorescence microscope (Olympus DP70, Japan) and quantification was performed by a person who was blinded to the experimental treatment. Condensed, shrunken, fragmented or irregular nuclei were considered signs of cell death. To quantitatively analyze changes in nuclear morphology, the percentage of cells with abnormal nuclei was calculated. All cells from 10 random microscopic fields at 40× magnification were counted and more than 500 cells in total were observed for each treatment group. The ratio of dead cells to total number of cells was then quantitatively analyzed. All cells from 10 random microscopic fields at 40× magnification were counted and more than 500 cells in total were observed for each treatment group. The ratio of dead cells to total number of cells was then determined. Each cell sample was resuspended in cell lysis buffer for an additional 10 min. Absorbance was measured at 412 nm using a microplate spectrophotometer. A standard curve was obtained from absorbance of the diluted commercial GSH that was incubated in the mixture as in samples. The results were obtained from three independent experiments performed in triplicate.

**Measurement of intracellular reactive oxygen species**

Intracellular ROS were measured by using the fluorescent probe 2,7-dichlorofluorescein diacetate (DCF-DA). The dye DCF-DA is oxidized to fluorescent 2,7-dichlorofluorescein (DCF) by intracellular hydrogen peroxide or low-molecular-weight peroxides. PC12 cells (1 $\times$ 10$^5$ cells/mL) were seeded in 96-well plates and incubated with MPP$^+$ alone or in the presence of paeonol for 24 h. Cells were incubated with 10 µM DCF-DA at 37°C for 30 min and then washed twice with PBS. Quantitative measurements of fluorescence readings were determined at 485/538 nm (excitation/emission) using a SpectraMax GEMINI EM fluorescent plate reader (Molecular Devices, USA) from cells in 96-well plates. The results were obtained from three independent experiments performed in triplicate.

**Measurement of mitochondrial membrane potential**

Mitochondrial membrane potential was measured using the fluorescence dye rhodamine 123 (Invitrogen). Cells were exposed to 10 µM rhodamine 123 for 25 min and then washed twice with HBSS before the fluorescence was determined with a SpectraMax GEMINI EM fluorescent plate reader (Molecular Devices, USA) at 511/534 nm. The results were obtained from three independent experiments performed in triplicate.

**Measurement of total glutathione level**

The level of total glutathione (reduced form GSH + oxidized form GSSG) was determined using glutathione reductase. PC12 cells were treated with MPP$^+$ alone or in the presence of paeonol for 24 h at 37°C, centrifuged at 412 × g for 10 min in a microplate centrifuge, the media removed and cells were washed twice with PBS. Cells were dissolved with 2% 5-sulfoisalicylic acid (100 µl) and incubated in 100 µl of the reaction mixture containing 22 mM sodium EDTA, 600 µM NADPH, 12 mM DTNB and 105 mM Na$_2$HPO$_4$, pH 7.5 at 37°C. Glutathione reductase (20 µl of 100 U/ml) was added, and the mixture incubated for an additional 10 min. Absorbance was measured at 412 nm using a microplate spectrophotometer. A standard curve was obtained from absorbance of the diluted commercial GSH that was incubated in the mixture as in samples. The results were obtained from three independent experiments performed in triplicate.

**Measurement of caspase-3 activity**

Caspase-3 activity was determined by using the caspase-3 activity assay kit (Life Science, USA). Briefly, after treatment, cells were harvested and washed with cold PBS. Each cell sample was resuspended in cell lysis buffer (100 mM HEPES, pH 7.4, 10% sucrose, 0.1% CHAPS, 1 mM EDTA, 10 mM dithiothreitol, 1 mM PMSE, 10 mg/ml pepstain, and 10 mg/ml leupeptin) and left on ice for 40 min. The lysed cells were then centrifuged to pellet the cellular debris. The supernatant containing 50 mg protein was incubated with 5 µM fluorogenic substrate peptide Z-DEVD-ER110 in 100 µl of lysis buffer. The intensity of fluorescence of Z-DEVD-ER110 substrate was measured in a fluorescence microplate reader using excitation at 496 nm and emission detection at 520 nm.

**Immunoblot analysis for cytochrome c**

After treatment, cells were collected and washed with PBS, then resuspended in ice-cold homogenizing buffer (250 mM sucrose, 1 mM dithiothreitol, 1 mM phenylmethylsulfonylfluoride, 1 mg/mL aprotinin and 1 mg/mL leupeptin). Cells were homogenized with a glass Dounce homogenizer. The homogenate was centrifuged at 1000 rpm for 10 min. Then the resulting
supernatant was centrifuged at 10,000 rpm (4°C, first for 10 min, and then for 1 h), to produce cytosol. 50 mg of each protein sample was subjected to SDS-polyacrylamide gel electrophoresis on a 12% gel. Then the protein was transferred onto a nitrocellulose membrane and immunoblotted with cytochrome c antibody as previously described [20]. Finally samples were incubated with goat anti-mouse IgG-horseradish peroxidase. The densitometric analysis of protein bands was performed using the image J analysis system.

Statistics
Data are presented as mean ± SEM. One-way ANOVA was performed followed by a Tukey post-hoc test to compare the significance between the individual groups. P-values less than 0.05 were considered significant.

All experimental procedures were approved by the Institutional Animal Ethical Committee of Sun Yat-sen University and were conducted according to the Guide for the Care and Use of Laboratory Animal of the National Institute of Health (Publication No. 80–23, revised 1996).

Results
Paeonolum attenuated MPP⁺-induced neurotoxicity in zebrafish
We first investigated the toxic effect of MPP⁺ in larval zebrafish, using different assessments including: overall morphology, number of DA neurons and locomotor activity. We first examined the overall morphological changes in larval zebrafish in the presence of MPP⁺. There were no significant morphological alterations observed in larval zebrafish receiving MPP⁺ up to 1000 μM, compared with untreated controls, indicating that MPP⁺ has no obvious effect on normal embryonic development of zebrafish (Figure 1A). We further studied whether MPP⁺ had a specific toxic effect on DA neurons in the ETvmat2:GFP line of zebrafish. ETvmat2:GFP fish embryos were exposed to different concentrations of MPP⁺ for 4 days starting at 24 hpf. The GFP expression of 5 dpf embryos was viewed under a fluorescence microscope. The disappearance of GFP signal was used as a readout of cell death, because apoptotic GFP-positive cells are rapidly cleared by circulating cells [21]. Consistent with previous data, we found that MPP⁺ induced a significant loss of neurons from the anterior group of the posterior tubercular (PTa), paraventricular organ (Pa), anterior group of the posterior tubercular (PTa) and intermediate hypothalamus neural cluster (Hi) but not from the telencephalon and locus coeruleus in the forebrain of larval zebrafish. These results suggest that MPP⁺ selectively damaged DA neurons in zebrafish in a concentration-dependent manner (Figure 1B.). As shown in Figure 2, we also found that MPP⁺ decreased the locomotor activity of larval zebrafish. The decrease in locomotor activity correlated well with the loss of PT neurons. We then examined the effect of paeonolum against MPP⁺-induced toxicity in zebrafish. Compared with vehicle treatment, 50–150 μM paeonolum significantly prevented the MPP⁺-induced decrease in locomotor activity in a concentration-dependent manner (P < 0.01).

Paeonolum reduced MPP⁺-induced PC12 cell damage in a concentration-dependent manner
The viability of PC12 cells was evaluated using the MTT assay and analysis of nuclear morphology. We first examined whether paeonolum has any effect on the viability of PC12 cells under normal culture conditions. Paeonolum (10–150 μM) did not affect PC12 cell viability when compared with vehicle-treated cells (data not

Figure 1 Paeonolum attenuated the MPP⁺-induced neurotoxicity in zebrafish. (A) Representative brightfield images of zebrafish larvae at 5 dpf. Treatment with MPP⁺ or paeonolum for up to 5 dpf did not adversely affect the normal development of zebrafish larvae. (B) Paeonolum attenuated MPP⁺-induced DA neurotoxicity in zebrafish larvae.
We examined whether paeonolum could protect PC12 cells against MPP⁺ toxicity. The relative MTT values in MPP⁺-treated cells were 59.48 ± 8.12% in the vehicle group and 61.22 ± 10.25%, 64.81 ± 10.74%, 70.76 ± 9.45%, 78.21 ± 7.84% and 82.85 ± 8.71% in cells treated with paeonolum used at 10, 25, 50, 100 or 150 μM, respectively. Compared with vehicle treatment, paeonolum (50–150 μM) significantly prevented the MPP⁺-induced reduction in MTT values in a concentration-dependent manner (P < 0.01). Similar results were obtained with the morphological analysis of cell nuclei. There were substantial morphological changes such as crenation and condensation in PC12 cells exposed to MPP⁺. Pretreatment with paeonolum significantly attenuated the MPP⁺-induced morphological changes in nuclei of the PC12 cells (Figure 3).

**Paeonolum reduced MPP⁺-induced intracellular ROS**

We further investigated the effect of paeonolum on MPP⁺-induced ROS production using DCF-DA, a specific dye for detecting levels of intracellular ROS. The results were expressed as percentage of fluorescence (% DCF-DA) relative to untreated controls. The relative intracellular ROS level in paeonolum alone treated cells was 102.77 ± 14.37%. Compared with control, paeonolum alone did not have any effect on basal ROS levels. The relative ROS levels in MPP⁺-treated cells were 213.12 ± 12.96% in the vehicle alone, 203.13 ± 10.37%, 196.87 ± 14.70%, 177.86 ± 16.69%, 157.37 ± 13.23% and 149.38 ± 11.98% in treatment groups with paeonolum used at 10, 25, 50, 100 and 150 μM, respectively. Compared with vehicle treatment, paeonolum (25–150 μM) significantly attenuated MPP⁺-induced ROS production in a concentration-dependent manner. The intensities of DCF-DA were dramatically increased following MPP⁺ for 24 h, whereas pretreatment with paeonolum significantly ameliorated the MPP⁺-induced increase in DCF-DA intensity (Figure 4).

**Paeonolum attenuated MPP⁺-induced reduction in mitochondrial membrane potential**

To examine whether paeonolum had a protective effect in mitochondria, we detected the mitochondrial membrane potential using rhodamine 123. Treatment of PC12 cells with 250 μM MPP⁺ for 24 h produced a significant loss in mitochondrial membrane potential compared with normal controls. The relative fluorescence values of rhodamine 123 in MPP⁺-treated cells were 55.43 ± 9.63% in the vehicle alone group, 57.83 ± 11.25%, 65.23 ± 10.21%, 59.37 ± 10.36%, 65.23 ± 10.21%, 77.08 ± 10.87% and 83.18 ± 11.27% in treatment groups with paeonolum used at 10, 25, 50,
Figure 3  Paeonolum protected against MPP⁺-induced neurotoxicity in cultured PC12 cells. Cells were preincubated with paeonolum for 30 min and then exposed to 250 μM MPP⁺ for an additional 24 h. Pretreatment with different concentrations of paeonolum significantly attenuated MPP⁺-induced PC12 cell damage. Cell viability is indicated by MTT values of each experimental group and are expressed as a percentage of the control group. Cellular morphological changes were detected by inverted microscopy. Representative images were selected from four independent experiments. Bar graph shows the percentage of cells with abnormal nuclei content in different experimental groups. Values are means ± SEM. *P < 0.01 compared with vehicle control. The results were obtained from four independent experiments performed in triplicate.

Figure 4  Paeonolum reduced MPP⁺-induced intracellular ROS production in PC12 cells. Cells were preincubated with paeonolum for 30 min and then exposed to 250 μM MPP⁺ for a further 24 h. Pretreatment with different concentrations of paeonolum significantly attenuated MPP⁺-induced intracellular ROS at 24 h following MPP⁺. Intracellular ROS is indicated by the DCF-DA values of each experimental group and are expressed as percentage of the control group. ROS was detected using DCF-DA. Representative images were selected from three independent experiments. Quantitative data are presented in the bar graph. Values are means ± SEM. *P < 0.01 compared with vehicle control. The results were obtained from three independent experiments performed in triplicate.
100 or 150 μM, respectively. Compared with vehicle treatment, paeonolum (50–150 μM) significantly attenuated the MPP⁺-induced reduction of mitochondrial membrane potential in a concentration-dependent manner.

Paeonolum restored MPP⁺-induced depletion of total GSH level
The total GSH levels were 9.74 ± 1.45 and 9.49 ± 1.44 nm/1 × 10⁵ cells, in the control and paeonolum-alone treated PC12 cells, respectively. Compared with control, paeonolum alone did not have any effect on basal GSH level. The total level of GSH was decreased to 7.45 ± 1.16 nm/1 × 10⁵ cells following incubation with 250 μM MPP⁺ for 24 h. The total GSH levels in MPP⁺-treated cells were 7.63 ± 1.11, 7.91 ± 1.17, 8.31 ± 1.16, 9.18 ± 1.36 and 9.37 ± 1.54 nm/1 × 10⁵ cells in groups treated with paeonolum at 10, 25, 50, 100 and 150 μM, respectively. Compared with vehicle treatment, paeonolum (50–150 μM) significantly restored the MPP⁺-induced depletion of total level of GSH in a concentration-dependent manner (Figure 5).

Paeonolum against MPP⁺-induced neurotoxicity involves the intrinsic mitochondrial pathway
The intrinsic mitochondrial pathway of cell death includes cytochrome c release and activation of caspase-3 and is the major death pathway involved in MPP⁺-induced toxicity. We first examined the potential effect of paeonolum on the MPP⁺-induced cytochrome c release from mitochondria using western blotting. As shown in Figure 6, MPP⁺ caused a significant (4.5-fold) increase in cytochrome c release compared with untreated controls. In contrast, paeonolum dose-dependently attenuated MPP⁺-mediated cytochrome c release. The release of cytochrome c was inhibited by 25.5%, 45.5% and 53.4% in MPP⁺ along with 50, 100 or 150 μM treatment using paeonolum, respectively. We further tested the effect of paeonolum on MPP⁺-induced activation of caspase-3 using the caspase-3 activity assay kit. As shown in Figure 7, caspase-3 activity was 193.13 ± 13.75% in the vehicle alone, 188.87 ± 15.45%, 177.87 ± 13.72%, 163.75 ± 11.12%, 148.63 ± 12.91% and 138.25 ± 11.63% in the groups treated with paeonolum at 10, 25, 50, 100 and 150 μM, respectively. Compared with vehicle treatment, MPP⁺ significantly increased caspase-3 activity compared with untreated controls. In contrast, treatment with paeonolum at 25 and 150 μM significantly attenuated MPP⁺-induced caspase-3 activity. Our results suggest that treatment with paeonolum inhibits MPP⁺-induced activation of caspase-3.

Discussion
In the present study, we have examined the protective effects of paeonolum against MPP⁺-induced toxicity in a transgenic zebrafish line (ETvmat2:GFP) and PC12 cells. Zebrafish are an excellent model for studying PD because their nervous system shares many similarities with humans [22]. In zebrafish, PT neurons in the posterior tuberculum of the ventral diencephalon are equivalent to the nigrostriatal system in humans. In addition, the pathways involved in processing, packaging and transport of DA are also conserved between zebrafish and humans. Similar to mammals, DA neurons in zebrafish take up MPP⁺, mainly through the high-affinity DA transporter. The accumulation of MPP⁺ inside neurons in turn inactivates the mitochondrial complex I of the respiratory chain and induces cell death. In the transgenic zebrafish ETvmat2:GFP line, most monoaminergic neurons, are labeled by GFP allowing clear observation of MPP⁺-induced DA neurodegeneration in living animals. Consistent with previous observations, we found that MPP⁺ induced a large loss of PT neurons, indicating selective damage to DA neurons in a concentration-dependent manner.

![Figure 5](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAABOAAAABACAYAAAAUqSbKAAAAABJRU5ErkJggg==)

Figure 5: Paeonolum restored the MPP⁺-induced decrease in the total level of GSH in PC12 cells. Cells were preincubated with paeonolum for 30 min and then exposed to 250 μM MPP⁺ for further 24 h. Pretreatment with different concentrations of paeonolum significantly attenuated MPP⁺-induced decrease in total GSH level at 24 h following MPP⁺. The total level of GSH (reduced form GSH + oxidized form GSSG) was determined using glutathione reductase. Quantitative data are presented in the bar graph. Values are means ± SEM. *P < 0.01 compared with vehicle control. The results were obtained from three independent experiments performed in triplicate.
manner. Furthermore, MPP⁺ also reduced locomotor activity in the zebrafish. Interestingly, the reduction of locomotor activity was closely associated with a loss of PT neurons in MPP⁺-treated zebrafish. Given that locomotor activity in zebrafish can be easily monitored and measured on a large scale, using an automated computer tracking system, this model may be good for high throughput screening of drugs to treat PD.

To explore whether the findings in zebrafish can be translated into a future clinical approach, we investigated the mechanisms underlying the neuroprotection of paonololum in PC12 cells. PC12 cells were used to established a MPP⁺-induced cellular model of PD because PC12 cells exhibit similar characteristics to DA neurons and have some of the physiological properties of DA neurons [23,24]. We found that incubation of PC12 cells with MPP⁺ at 250 μM for 24 h induced up to 50–60% of PC12 cell death which is in agreement with previous studies [10,25]. Similar to the findings in our zebrafish model using MPP⁺, paonololum reduced MPP⁺-induced PC12 toxicity in a concentration-dependent manner, indicating that zebrafish can serve as a valuable model for translational research in the field of PD.

Substantial clinical and experimental evidence has demonstrated the critical role of mitochondrial dysfunction in the pathogenesis of PD [2,6]. Mitochondria are the major source of ROS production. MPP⁺ is a mitochondrial toxin and specifically inhibits mitochondrial complex I, which further promotes the opening of the mitochondrial permeability pore and causes the collapse of the mitochondrial membrane potential, causing excessive generation of ROS [1,14,26]. Excessive ROS production can damage the respiratory chain and further stimulate ROS, forming a vicious cycle resulting in cell death. Consistent with this idea, MPP⁺ significantly reduced the mitochondrial membrane potential in PC12 cells, whereas pretreatment with paonololum attenuated the degree of MPP⁺-induced loss of mitochondrial membrane potential, suggesting that paonololum may have a direct protective action on mitochondria. It is generally believed that the neurotoxic effects of MPP⁺ are mediated by oxidative stress. Although the antioxidant activity of paonololum has been demonstrated in different systems, it is not clear whether antioxidant activity of paonololum is also contributed to its neuroprotective effect in our model of MPP⁺ toxicity. We found that paonololum attenuated MPP⁺-induced ROS production in a concentration-dependent manner. In addition, paonololum also rescued the reduction of the activity of the intracellular antioxidant GSH. Given that paonololum did

Figure 6 Paonololum inhibited MPP⁺-induced the release of cytochrome c. PC12 cells were treated with 250 μM MPP⁺ for 24 h in the presence or absence of paonololum (50, 100, 150 μM). Cytochrome c release was determined by Western blot analysis. The amount of cytochrome c was estimated by densitometric analysis of each protein band. The data are represented as means ± SEM for three independent experiments. *P < 0.01 vs. group treated with MPP⁺ alone.

Figure 7 Paonololum inhibited MPP⁺-induced increase in caspase-3 activity. PC12 cells were treated with 250 μM MPP⁺ for 24 h in the presence or absence of paonololum (50, 100, 150 μM). The data are represented as means ± SEM for three independent experiments. *P < 0.01 vs. group treated with MPP⁺ alone.
not have any direct effect on GSH activity on its own, this beneficial effect may have been indirectly related to its action as a general antioxidant.

Pathologically, PD is caused by a selective loss of DA neurons in the SN. Increasing evidence from human studies on postmortem brains from PD patients, suggests that apoptotic cell death is most likely contribute to the neuronal loss observed in PD. Similarly, MPP⁺ induces apoptosis in both animals and cell cultures via affecting the mitochondrial pathway. As an inhibitor of mitochondrial complex I, MPP⁺ triggers opening of the mitochondrial permeability transition pore, induces release of apoptotic proteins such as cytochrome c into the cytoplasm and initiates caspase-3 activation, finally resulting in biochemical and morphological alterations suggestive of apoptosis. We found that paeonolum significantly suppressed MPP⁺-induced loss of mitochondrial membrane potential, cytochrome c release and caspase-3 activity, suggesting that paeonolum is able to attenuate MPP⁺-induced toxicity through inhibition of the mitochondrial cell death cascade.

Conclusion
Here, we have demonstrated the neuroprotective action of paeonolum against MPP⁺ toxicity in zebrafish and PC12 cells. Paeonolum exerts its protective action through reducing overproduction of ROS, attenuating loss of mitochondrial membrane potential and restoring GSH levels in MPP⁺-treated PC12 cells. The low toxicity, antioxidant properties and ease to cross the BBB warrant further investigation of this compound.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XLL, ZP and XLY designed and conceived the study. XLL, YHL, FJS, CHY, LS, BKH, FWH performed the experiments. XLL and YHL wrote the manuscript. All authors have read and approved the final manuscript.

Acknowledgments
This study was supported by grants from the National Key Clinical Department, National Key Discipline, Guangdong Key Laboratory For Diagnosis and Treatment of Major Neurological Diseases, the National Natural Science Foundation of China (No. 81371255, 81100936), Doctoral Program of Higher Education of China (No. 20111711100558), Guangdong Technological grant (No. 2010B050700024, 2011B050400031, 2012B031800107), Guangdong Department of Science & Technology Translational Medicine Center grant (No. 2011A03030002) and the National Natural Science Foundation of Guangdong Province (No. S201110004860). The authors would like to offer special thanks to the North Center of National Zebrafish Resources of China for their technological support with the zebrafish.

Author details
1Department of Neurology, Guangdong Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. 2National Key Clinical Department, Guangdong Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. 3Key Discipline of Neurology, Guangdong Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. 4Department of Clinical Laboratory, Cancer Center of Sun Yat-sen University, Guangzhou 510060, China. 5Department of Geriatrics, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. 6Neurosurgery Intensive Care Unit, Department of Critical Care Medicine, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

Received: 3 December 2014 Accepted: 22 April 2015

Published online: 29 April 2015

References
1. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909.
2. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease. Nat Clin Pract Neurol. 2008;4:600–9.
3. Banerjee R, Starkov AA, Beal MF, Thomas B. Mitochondrial dysfunction in the limelight of Parkinson’s disease pathogenesis. Biochim Biophys Acta. 2007;1792:651–63.
4. Ebiadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson’s disease Antioxid. Redox Signal. 2003;5:319–35.
5. Mandemakers W, Morsia VA, De Strooper B. A cellular biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J Cell Sci. 2007;120:1707–16.
6. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Mariden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990;54:823–7.
7. Schapira AH, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, et al. Mitochondria in the etiology and pathogenesis of Parkinson’s disease. Ann Neurol. 1998;44:589–98.
8. Langston JW, Ballard P, Tetrad JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:797–80.
9. Tetrad JW, Langston JW. MPTP-induced parkinsonism as a model for Parkinson’s disease. Acta Neurol Scand Suppl. 1989;126:35–40.
10. Morangi ME, Piccardi MP, Bernardi F, Corsini GU, Del Zompo M. Evaluation of the toxicity of the dopaminergic neurotoxic MPTP and MPP⁺ in PC12 pheochromocytoma cells: binding and biological studies. Neurosci Lett. 1988;94:349–54.
11. Link CD. Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech Ageing Dev. 2001;122:1639–49.
12. Nars R, Blaely RD. The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Annu Rev Pharmacol Toxicol. 2003;43:521–44.
13. Wen L, Wei W, Gu W, Huang P, Ren X, Zhang Z, et al. Visualization of monoaminergic neurons and neurotransmitters in mice by live transgenic zebrafish. Dev Biol. 2008;314:4–92.
14. Cassarino DS. The parkinsonian neurotoxin MPP⁺ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta. 1999;1453:49–62.
15. Abdel-Salam OM. Drugs used to treat Parkinson’s disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008;7:321–42.
16. Li HWS, Yang Q, Xin Y, Cao W, Zang B, Wang JB, et al. LC tissue distribution study of paeonolin in rats after oral administration. Chromatographia. 2011;73:495–500.
17. Hsieh CL, Cheng CY, Tsai TH, Lin IH, Liu CH, Chiang SY, et al. Paeonol reduced cerebral infarction involving the superoxide anion and microglia activation in ischemia-reperfusion injured rats. J Ethnopharmacol. 2006;106:208–15.
18. Kawakami K, Takeda H, Kawakami N, Kobayashi M, Matsuda N, Mishina M. A transposon-mediated gene trap approach identifies developmentally regulated genes in zebrafish. Dev Cell. 2004;7:133–44.
19. Meng A, Tang H, Ong BA, Farrell MJ, Lin S. Promoter analysis in living zebrafish embryos identifies a cis-acting motif required for neuronal expression of GATA-2. Proc Natl Acad Sci U S A. 1997;94:2667–72.
20. Luo X, Budhirajo J, Zou H, Slaughter C, Wang X, Bld, A. Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481–90.
21. Lopez-Schier H, Hudspeth AJ. A two-step mechanism underlies the planar polarization of regenerating sensory hair cells. Proc Natl Acad Sci U S A. 2006;103:18615–20.
22. Bruni G, Lakhani P, Kokel D. Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish. Front Pharmacol. 2014;5:153.

23. Presse F, Cardona B, Borsu L, Nahon JL. Lithium increases melanin-concentrating hormone mRNA stability and inhibits tyrosine hydroxylase gene expression in PC12 cells. Brain Res Mol Brain Res. 1997;52:270–83.

24. Zachor DA, Moore JF, Brezausek C, Theibert A, Percy AK. Cocaine inhibits NGF-induced PC12 cells differentiation through D(1)-type dopamine receptors. Brain Res. 2000;869:85–97.

25. Lee CS. Modulation of 1-methyl-4-phenylpyridinium-induced mitochondrial dysfunction and cell death in PC12 cells by K(ATP) channel block. J Neural Transm. 2007;114:297–305.

26. Nicotra A, Parvez S. Apoptotic molecules and MPTP-induced cell death. Neurotoxicol Teratol. 2002;24:599–605.